Defunct Company
Total Trials
16
As Lead Sponsor
13
As Collaborator
3
Total Enrollment
1,643
NCT00140374
Vaccination Priming and Vaccine Boosting Trial of Allogeneic Human GM-CSF Gene Transduced Irradiated Prostate Cancer Cell Vaccines (GVAX® Vaccine for Prostate Cancer)
Phase: Phase 1/2
Role: Lead Sponsor
Start: Dec 31, 1998
Completion: Feb 28, 2001
NCT00140387
Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Cell Vaccines (Allogeneic Prostate GVAX®)
Start: May 31, 1999
Completion: Mar 31, 2001
NCT00140400
Prime-Boost Dose Scheduling Trial for Human GM-CSF Gene Transduced Irradiated Prostate Allogeneic Cancer Vaccine (Allogeneic Prostate GVAX®) in Patients With Hormone-Refractory Prostate Cancer
Completion: Jan 31, 2001
NCT00116441
Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma
Start: Oct 31, 2000
Completion: Oct 31, 2004
NCT00116467
Vaccination in the Peripheral Stem Cell Transplant Setting for Acute Myelogenous Leukemia
Phase: Phase 2
Start: Mar 31, 2001
Completion: Jan 31, 2006
NCT00140348
Dose Escalation and Efficacy Trial of GVAX® Prostate Cancer Vaccine
Start: Dec 31, 2001
Completion: Apr 30, 2005
NCT00245362
A Phase II Trial of CG 8020 and CG 2505 in Patients With Nonresectable or Metastatic Pancreatic Cancer
Start: Jun 30, 2002
Completion: Jun 30, 2004
NCT00089726
A Cancer Vaccine (CG8123) Given With and Without Cyclophosphamide for Advanced Stage Non-Small Cell Lung Cancer (NSCLC)
Start: Mar 31, 2003
NCT00089856
GVAX® Vaccine for Prostate Cancer vs Docetaxel & Prednisone in Patients With Metastatic Hormone-Refractory Prostate Cancer
Phase: Phase 3
Start: Jul 31, 2004
Completion: Oct 31, 2008
NCT00103428
Intravenous CG7870 in Combination With Docetaxel in Patients With Metastatic Hormone-Refractory Prostate Cancer
Start: Aug 31, 2004
Completion: Not specified
NCT01510288
Phase 1 Trial of Ipilimumab and GVAX in Patients With Metastatic Castration-resistant Prostate Cancer
Phase: Phase 1
Role: Collaborator
Start: Nov 30, 2004
Completion: Nov 30, 2011
NCT00109655
Dose-Escalation Study of CG0070 for Bladder Cancer After BCG (Bacillus Calmette-Guerin) Failure
Start: Apr 30, 2005
Completion: Sep 30, 2010
NCT00133224
Docetaxel in Combination With GVAX ® Immunotherapy Versus Docetaxel and Prednisone in Prostate Cancer Patients
Start: Jul 31, 2005
Completion: Jun 30, 2009
NCT00122005
GVAX in Advanced Prostate Cancer Patients Made Lymphopenic
Completion: Jul 31, 2005
NCT00577356
Docetaxel and Immunotherapy Prior to Prostatectomy for High-Risk Prostate Cancer
Start: Feb 29, 2008
Completion: Sep 30, 2008